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We have previously shown that modification of polyphenols with a ferrocenyl group can 
dramatically enhance their cytotoxicity. We now present two new [3]ferrocenophane 
compounds, one of which has an antiproliferative effect seven times stronger than the 
corresponding noncyclic species, with IC50 values of 90 and 94 nM on hormone-
independent MDA-MB-231 breast and PC-3 prostate cancer cell lines, respectively. 
Solubility studies in water using methylated β-cyclodextrin and electron transfer studies are 
also presented. 
 Introduction 
Bioorganometallic chemistry is driving an increasing amount of growth in drug 
design.
1-3 As part of an ongoing study of biologically active organometallic compounds, 
we have described a reasoned approach to preparing a new family of metallocene 
complexes with strong antitumor potential. This approach involves the substantial 
modification of the biological properties of polyphenols by the covalent addition of a 
ferrocenyl group to the organic skeleton.
4-11 Compound 1 (Chart 1) is estrogenic on MCF-
7 hormone-dependent breast cancer cells, promoting cell proliferation, while 2, bearing 
a ferrocenyl entity, produces a powerful antiproliferative effect on both MCF-7 cells and 
MDA-MB-231 hormone-independent breast cancer cells.
4 Likewise, while the natural 
polyphenol resveratrol 3 has an IC50 value as high as 20 μM on MDA-MB-231 cells,
12 the 
IC50 value for 2 is on the order of 0.5 μM,
4 a 40-fold improvement. Thus, although organic 
polyphenols are not efficacious at a therapeutic level, modification with Fc
a vastly 
improves their antiproliferative properties in vitro. 
It should be emphasized that the simple presence of a ferrocenyl group is not 
sufficient to generate cytotoxic compounds.
11 For example, a proliferative effect was 
found on estrogen receptor (ER) positive cells for the molecule created by the attachment 
of a ferrocenyl group to the 17β position of the natural hormone estradiol.13 Both the 
position and the structural pattern in which Fc is inserted are important, and the motif 
[Fc]-[conjugated spacer]-[ p-phenol] seems to be crucial for strong cytotoxic effects; a 
change in the position of either the OH or ferrocenyl group resulted in a weakened 
cytotoxic effect.
5-9 
Our aim is now to seek related molecules that may have even higher efficacy than 2. 
We envisaged solutions based on new structures while preserving the key ferrocenyl-
phenol motif, and it seemed to us that constrained ring structures were particularly 
appropriate. Rigid molecules can bind more strongly to a receptor than their flexible 
analogues if they have the proper geometry for entering the active site, while a flexible 
molecule must adopt such a geometry, causing entropy loss and weaker binding. 
Accordingly, molecules 4 and 5, based on the [3]ferrocenophane motif, were prepared and 
studied (Chart 2). Molecule 4 possesses a direct linkage between the cyclopentadienyl ring 
and the double bond, while the other cyclopentadienyl is attached to the double bond by 
a two-carbon bridge. In 5, the ferrocenyl is symmetrically linked to the double bond by a 
single-carbon bridge. 
 
Results 
Compound 4 was obtained in 28% yield via a McMurry cross-coupling reaction with 
the ferrocenophanone 6 and 4,4’-dihydroxybenzophenone (Scheme 1). Compound 6 could 
be obtained via the reaction of Fc with acryloyl chloride in the presence of aluminum 
chloride, 
14,15
 or alternatively, via the acylation of Fc with ethyl mono-malonate,
16
 
followed by Clemmensen reduction of the resulting ketoester and hydrolysis and 
cyclization of the ferrocenylpropionic acid formed. The synthesis of 5 required 1,1’-(2-
ketotrimethylene)ferrocene, which has been previously reported.
17 A McMurry cross-
coupling reaction of this compound with 4,4’-dihydroxybenzophenone gave 5 as a yellow 
powder in 22% yield. 
The relative binding affinity (RBA) to ER, lipophilicity, and 
proliferative/antiproliferative effects against the MCF-7 ER+ breast, the MDA-MB-231 
ER- breast, and the PC-3 AR- prostate cancer cell lines are reported in Table 1, along 
with the values obtained for the noncyclic compound 2 for comparison. Molecules 4 and 
5 recognize ERα and ERβ, present in varying degrees in MCF-7 cells, with overall values 
on the same order of magnitude as that of 2. However, 4 and 5 exhibit different behavior on 
the growth of MCF-7 cells. After five days of culture, 4 is estrogenic at low 
concentration (10 nM; 124% vs control) and becomes cytotoxic at higher concentration 
(100 nM; 69%). At 10 nM, 5 is estrogenic after 4 days of culture (118%) but, unusually, 
becomes cytotoxic after 5 days of culture (80%). IC50 values of 4 μM for 4 and of 1 μM for 
5 can be estimated for MCF-7 cells after five days of incubation. It is clear that there is a 
competition on this cell line between the estrogenic (positive) and cytotoxic (negative) 
effects, and it seems from these results that 4 is more estrogenic than 5. Surprisingly, this 
could not be predicted from the RBA values, which are quite similar. Overall, the values for 
MCF-7 cells are on the same order of magnitude as that of the noncyclic diphenol 2. 
Compound 4 shows an exceptional antiproliferative effect on the hormone-independent 
MDA-MB-231 and PC-3 cells, with an IC50 value of 0.09 μM, an order of magnitude 
more cytotoxic than 5, which lacks conjugation between the phenol and the ferrocenyl 
groups. The cytotoxic effect of compound 2, lacking the ferrocenophane structure but 
possessing a conjugated system, falls intermediate between 4 and 5. 
 
Table 1. RBA, log Po/w, and the Effect on Cancer Cell Growth of 2, 4, and 5  
 RBA(%)  IC50 (μM)
a
 
 ERα ERβ log Po/w MDA-MB-231 PC-3 
2 9.6 ± 0.9 16.3 ± 1.5 5.0 0.64 ± 0.06 0.7 (1 exp) 
4 7.2 ± 0.7 4.84 ± 0.4 4.6 0.09 ± 0.01 0.094 ± 0.006 
5 7.6 ± 0.6 15.4 ± 0.4 4.8 0.96 ± 0.03 1.08 ± 0.02 
a
 Measured after 5 days of culture (mean of two independent experiments). 
 
Chart 1. Replacement of Ph with Fc on 1 Imparts Cytotoxicity 
 
 
Chart 2. Two New Cytotoxic [3]Ferrocenophanes Studied in This Report 
 
Scheme 1 
 
 
The presence of partially methylated β-cyclodextrin (CD) does not hinder the in vitro 
cytotoxic effects of 4. MDA-MB-231 incubation with the CD-4 complex (obtained by addition 
to an aqueous solution of 2 equiv of CD and allowed to dissolve overnight) gave identical 
results between the free and encapsulated forms (10% cell survival at 10
-6 M). The 
complexation of 4 with CD in water was investigated by electrochemistry, as previously 
reported for 2.
18 Qualitatively, the time required to dissolve 4 in H2O in the presence of CD 
was fast compared to that of 2 (20 min vs 1 h). The cyclic voltammogram (CV) of the Fc/Fc
+ 
redox couple obtained with the solution of CD-2 (see Supporting Information) exhibited a 
plateau shape characteristic of a consecutive chemical-electrochemical mechanism, indicating 
that the oxidation process was limited by the dissociation step of the complex formed between 
the CD and compound 2. The peak shape and the faster electron transfer obtained with CD-4 
are thus consistent with a weak complexation and a fast decomplexation dynamic. 
 
 
Figure 1. Cyclic voltammograms of 4 (1 mM, scan rate 100 mV/s, left) and 5 (0.3 
mM, scan rate 50 mV/s, right) in the presence of varying concentrations of imidazole. 
As observed in Figure 1, in the absence of imidazole, compounds 4 and 5 exhibit 
a monoelectronic oxidation process at 0.46 V (4) and 0.48 V (5), ascribed to the 
ferrocenyl oxidation. Upon addition of increasing amounts of base, the intensities of the 
oxidation waves of both compounds increase, indicating an electron transfer between the 
phenol and the ferricenium groups prior to the reverse sweep. 
 
Discussion and Conclusions 
Compound 4 represents a major advance in the study of antiproliferative 
organometallic compounds, with an IC50 value on ER- cells several times lower than our 
noncyclic lead compound 2. On ER+ cells, 4 displays a combination of estrogenicity and 
cytotoxicity, which suggests that it should be more efficacious against hormone-
refractory tumors. However, to create a compound active against both types of cells, one 
could eliminate the estrogenic effect by replacing one hydroxyl group with the lateral chain 
-O(CH2)xN(CH3)2 (x=3-5), as we have previously shown for the hydroxyferrocifen series.
19
 
Compound 4 is itself too hydrophobic to envision its intravenous administration, thus 
possibly limiting its bio-availability for clinical applications. The potency of 4 against 
MDA-MB-231 cells when encapsulated by partially methylated β-cyclodextrin was 
maintained. The ability of cyclodextrins to include part of an organometallic complex in 
their internal hydrophobic cavities has been amply demonstrated,
20 and both the 
stoichiometry and the orientation of ferrocenyl depend on the size of the cyclodextrin. The 
fast complexation/decomplexation dynamic observed suggests that the ferrocenyl group is 
situated in an equatorial orientation
21 in such a way that hydrophobic interactions 
between the phenyl and methoxy groups are minimized. 
One of the possible mechanisms that we have identified to explain the cytotoxic effect 
of ferrocenyl phenols on various cancer cells is based on the in situ transformation to a 
quinone methide (QM), a process that is mediated by the ferrocenyl group and can be 
followed by electrochemistry.
9 Electrochemical experiments suggest that transformation to a 
QM can be realized for 4 and 5. In this context, the intramolecular proton coupled electron 
transfer from the phenol to the ferricenium in 4 can be explained by the classical π-
delocalized mechanism. For the unconjugated 5, one must consider either that the 
electron transfer proceeds “through space”, or via the formation of an intermediate α-
methylene radical (such α-methylene ferricenium molecules possess acidic protons),22 
which can delocalize over the π system and undergo an additional oxidation step to yield 
the QM. 
It has recently been shown that resveratrol can affect cancer cell growth and induce 
apoptosis in launching the synthesis of endogenous ceramide, a bioactive sphingolipid.
12,25 
Ceramide is a promising pharmacological target, particularly for cancer therapy. Many 
drugs that promote the production of ceramide have been proven to be more effective on 
malignant cells than on healthy tissue,
12 and this is also the case with compound 2.
23-25 
The idea that compound 4, the most effective to date, could possess a high ceramide-
mediated proapoptotic activity on human breast cancer cells is however just a working 
hypothesis and will be explored in the future. It remains that 4 shows a very strong 
antiproliferative effect against hormone independent cancer cell lines, and this next 
generation of cyclic ferrocenyl phenols is currently being expanded for future study. 
 
Experimental Section 
All reactions were performed under inert atmosphere, THF was distilled from 
Na/benzophenone, and commercial reagents were used without further purification. 
Purity of >95% was confirmed via elemental analysis for 4 and analytical HPLC for 5. 
1 ,1 ’ - {1 - [1 , 1 - B i s ( 4 - hydr oxyph eny l )m et hy l ide ne ] t r im e thy lene }  
f erroc ene  (4). To a suspension of 3.07 g (46.9 mmol) of Zn dust in 100 mL of THF 
and 4.55 g (2.64 mL, 24 mmol) of TiCl4 was added at -10 °C. The cooling bath was 
removed, and the mixture was refluxed for 1 h. After cooling to rt, 3.79 g (3.87 mL, 47.9 
mmol) of anhydrous pyridine was added and the mixture was stirred for 5 min. A 
solution of 1.92 g (8 mmol) of [3]ferrocenophan-1-one and 1.71 g (8 mmol) of 4,4’-
dihydroxybenzophenone in 30 mL of THF was added and the mixture was refluxed for 90 
min. After cooling to rt, the mixture was hydrolyzed with 100 mL of 8% aq K2CO3. The 
reaction mixture was extracted with several 100 mL portions of diethyl ether. The 
organic phase was washed with water (2x200 mL) and brine (200 mL), dried over MgSO4, 
and evaporated to dryness. Product 4 (2nd yellow fraction) was isolated by flash 
-1 
chromatography on silica gel (n-pentane:diethyl ether 2:1). Yield=1.57 g (47%, purity 90-
95%). A second column using 60 mL of silica gel and n-pentane:diethyl ether 4:1 
yielded a yellow powder, which was recrystallized from acetone or from a mixture of 
ethyl acetate (5 mL) and n-pentane (80 mL) at 4 °C. After 48 h, the organic solution was 
removed and the yellow crystals washed twice with n-pentane. Yield= 0.95 g (28%). 
1
H 
NMR (300.13 MHz, acetone-d6): 8.31 (s, 1H, OH), 8.10 (s, 1H, OH), 7.07 (d, J=8,7 Hz, 
2H, Ar), 6.85 (d, J=8,7 Hz, 2H, Ar), 6.84 (d, J=8,7 Hz, 2H, Ar), 6.54 (d, J=8,7 Hz, 2H, Ar), 
4.25 (t, J=1,7 Hz, 2H, C5H4), 3.98 (m, 4H, C5H4), 3.92 (t, J=1,7 Hz, 2H, C5H4), 2.70 (m, 
2H, CH2), 2.34 (m, 2H, CH2). 
13
C NMR (75.48 MHz, acetone-d6): 157.0 (C), 156.4 (C), 
141.5 (C), 136.0 (C), 135.9 (C), 133.4 (C), 132.4 (2CH), 131.2 (2CH), 115.7 (2CH), 114.8 
(2CH), 87.6 (C C5H4), 84.9 (C C5H4); 71.0 (2CH C5H4), 70.8 (2CH C5H4), 69.1 (2CH 
C5H4), 68.8 (2CH C5H4), 41.5 (CH2), 29.1 (CH2). Analysis: calcd for C26H22FeO2: C 
73.95%, H 5.25%; found: C 73.79%, H 5.34%. HRMS (CI – CH4): calcd for 
C26H22FeO2: 423.1047; found: 423.1040 (M+H)
+
. 
1,1’-{2-[1,1-Bis (4-hydroxyphenyl) methylidene] trimethylene} ferrocene (5). 
Compound 5 was synthesized as described for 4 but at 5% scale, with similar workup. 
Yield=0.038 g (0.090 mmol, 22%) of yellow powder. 
1
H NMR (300.13 MHz, acetone-
d6): 8.22 (s, 2H, OH), 7.16 (d, J=8.7 Hz, 4H, Ar): 6.80 (d, J=8.7 Hz, 4H, Ar), 4.11 (t, 
J=1.9 Hz, 4H C5H4), 3.99 (t, J=1.9 Hz, 4H, C5H4), 2.81 (s, 4H, CH2). 
13
C NMR (75.48 
MHz, acetone-d6): 156.7 (C), 141.7 (C), 138.6 (C), 135.8 (C), 131.0 (2 x 2CH), 115.7 (2 x2 
CH), 83.5 (2 C C5H4), 70.3 (2x 2CH C5H4), 66.9 (2x2CH C5H4), 28,3 (2CH2). IR (KBr, 
cm
-1
): 1609, 1508, 1430, 1220, 1197, 831. HRMS (CI-CH4): calcd for C26H23FeO2: 
423.1047 (M+H)
+
; found: 423.1034 (M+H)
+
. 
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Analytical Instrumentation 
Infrared spectra were obtained on an IRFT BOMEM Michelson-100 spectrometer equipped 
with a DTGS detector as a KBr plate. 
1
H and 
13
C NMR spectra were recorded on a 300 MHz 
Bruker spectrometer. Mass spectrometry was performed with a Nermag R 10-10C 
spectrometer. Melting points were measured with a Kofler device. Elemental analyses were 
performed by the microanalysis service of CNRS at Gif sur Yvette. Electrochemical 
experiments were performed Cyclic voltammograms were obtained utilizing a Princeton 
Applied Research potentiostat. Analyte solutions were 1 mM in DMF with 0.1 M Bu4NBF4 
supporting electrolyte. Cyclic voltammetry experiments were performed at room temperature 
under an argon atmosphere in a three-electrode cell. The reference electrode was an SCE 
(Tacussel), which was separated from the solution by a bridge compartment filled with the 
same solvent/supporting electrolyte solution as used in the cell. The counter electrode was a 
platinum mesh (Goodfellow). The platinum working electrode was home-made (0.5 mm 
diameter; Goodfellow). 
 
Synthesis of Intermediates 
Ethyl ferrocenoylacetate, 6 was prepared by slightly modified procedure for acylation of 
ferrocene with acyl trifluoroacetate.
1
 To a stirred solution of 13.2 g of ethyl mono-malonate 
and 21 g (14 ml) of trifluoroacetic anhydride in 100 ml of dichloromethane was added 18.6 g 
of ferrocene. After 5 min a solution of 30 ml of methanesulfonic acid in 50 ml of 
dichloromethane was added. The resulting violet mixture was stirred at room temperature. 
After 4 h the reaction mixture was poured onto ice (300g) and the resulting solution was 
neutralized by addition of solid NaHCO3. Products were extracted with DCM. 
Chromatography on silica gel (DCM – ethyl acetate 95 - 5) gave 18 g of pure product. 1H, 13C 
NMR confirmed the structure as reported in the literature.
2
 
 
Ethyl 3-ferrocenylpropionate, 7 was prepared as previously described
3
 for the synthesis of 
ferrocenylbutyric acid. To a mixture of 70 g of zinc dust and 10 g of Hg(OAc)2 in 150 ml of 
water, 5 ml of 37% HCl was added and the resulting mixture was stirred for 10 min. The 
aqueous solution was decanted and the Zn/Hg was washed 4 times with 200 ml portions of 
water. The mixture of Zn/Hg, the solution of 10 g of FcCOCH2COOEt in 160 ml of toluene, 
40 ml of water and 60 ml of 37% HCl was stirred and refluxed for 4 h (only one product on 
TLC – hexane). After cooling to room temperature the organic solution was separated and the 
inorganic residue extracted with toluene. The toluene solution was washed with sat. aq. 
NaHCO3 and dried with MgSO4. Evaporation of the solvents gave the product in quantitative 
yield. The 
1
H and 
13
C NMR spectra confirmed the structure as reported in the literature.
4
 
 
Ferrocenylpropionic acid, 8. A mixture of 9 g of 7, 25 ml of EtOH, and 100 ml of 20% aq. 
solution of NaOH was refluxed. After 3 h the resulted solution was diluted with 200ml of 
water and extracted with several portion of diethyl ether and the aqueous solution was filtered 
and acidified with conc. HCl to pH 1. 8 was extracted twice with 100 ml portions of DCM, 
organic solution was washed twice with 200 ml portions of water and dried. Evaporation of 
solvent gave 5.3 g of pure 8. Crystallization from DCM – n-pentane gave product as a yellow 
powder. 
1
H, 
13
C NMR confirmed the structure as reported in the literature.
5
 
 
  
Biochemical studies 
Materials. Stock solutions (1 x 10
-3
 M) of the compounds to be tested were prepared in 
DMSO and were kept at 4 °C in the dark; under these conditions they are stable at least two 
months. Serial dilutions in DMSO were prepared just prior to use. Dulbecco’s modified eagle 
medium (DMEM) with phenol red/Glutamax I, Dulbecco’s modified eagle medium (DMEM) 
without phenol red, Glutamax I and fetal bovine serum (FBS) were purchased from 
Invitrogen; estradiol from Sigma. PC-3 and MDA-MB-231 cells were from American Type 
Culture Collection (ATCC, LGC Promochem). Sheep uteri weighing approximately 7 g were 
obtained from the slaughterhouse at Mantes-la-Jolie, France. They were immediately frozen 
and kept in liquid nitrogen prior to use. 
 
Determination of the Relative Binding Affinity (RBA) of the compounds for ERα and 
ERβ. RBA values were measured on ERα from lamb uterine cytosol and on ERβ Panvera 
purchased from Invitrogen ( France ). Sheep uterine cytosol prepared in buffer A (0.05 M 
Tris-HCL, 0.25 M sucrose, 0.1% ßmercaptoethanol, pH 7.4 at 25 °C) was used as a source of 
ERα. For ERβ, 10 μl of the solution containing 3500 pmol/ml were added to 16 ml of buffer B 
(10% glycerol, 50 mM Bis-Tris-Propane pH = 9, 400 mM KCl, 2 mM DTT, 1 mM EDTA, 
0.1% BSA) in a silanized flask. Aliquots (200 μl) of ERα in glass tubes or ERβ in 
polypropylene tubes were incubated for 3 h at 0 °C with [6,7-3H]-estradiol (2 x 10
-9
 M, 
specific activity 1.62 TBq/mmol, NEN Life Science, Boston MA) in the presence of nine 
concentrations of the hormones to be tested. At the end of the incubation period, the free and 
bound fractions of the tracer were separated by protamine sulfate precipitation. The 
percentage reduction in binding of [3H]-estradiol (Y) was calculated using the logit 
transformation of Y (logitY: ln[y/1-Y] versus the log of the mass of the competing steroid. 
The concentration of unlabeled steroid required to displace 50% of the bound [3H]-estradiol 
was calculated for each steroid tested, and the results expressed as RBA. The RBA value of 
estradiol is by definition equal to 100%. 
 
Culture conditions. Cells were maintained in a monolayer culture in DMEM with phenol 
red/Glutamax I supplemented with 9% fetal bovine serum at 37 °C in a 5% CO2/air-
humidified incubator. For proliferation assays, PC-3 and MDAMB-231 cells were plated in 1 
mL of DMEM without phenol red, supplemented with 9% decomplemented and hormone-
depleted fetal bovine serum, 0.9% kanamycin, 0.9% Glutamax I and incubated. The following 
day (D0), 1 mL of the same medium containing the compounds to be tested was added to the 
plates. After 3 days (D3) the incubation medium was removed and 2 mL of the fresh medium 
containing the compounds was added. After 5 days the total protein content of the plate was 
analyzed as follows: cell monolayers were fixed for 1 h at room temperature with methylene 
blue (1mg mL
-1
 in 50:50 water/MeOH mixture), then washed with water. After addition of 
HCl (0.1 M, 2 mL), the plate was incubated for 1 h at 37 °C and then the absorbance of each 
well (6 wells for each concentration) was measured at 655 nm with a Biorad 
spectrophotometer. The results are expressed as the percentage of proteins versus the control. 
  
Cyclic voltammogram of CD-4 
 
 
 
Figure S1. Cyclic voltammogram of a) 4 and b) 2 (1 mM) in H2O + Na2SO4 (0.1 M) recorded 
at a glassy carbon electrode (3 mm diameter) at 50 mV s
-1
, in the presence of 20 eq. Me-β-
CD. O1 and R1 refer to the oxidation and reduction waves, respectively. 
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